Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.72 |
| ▸ | IDO1 | P14902 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27907644 | 0.87 | ADRA1A (0.57) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| SCHEMBL479514 | 0.84 | TAAR1 (1.00) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| SCHEMBL29491077 | 0.84 | TAAR1 (1.00) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| SCHEMBL29350908 | 0.83 | APLNR (0.63) | ADRA1ATAAR1IDO1HTR2ACA12 | |
| SCHEMBL153750 | 0.83 | APLNR (0.63) | ADRA1ATAAR1IDO1HTR2ACA12 | |
| SCHEMBL5252421 | 0.83 | IDO1 (0.66) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| Hydrochloric Acid SCHEMBL25232952 | 0.82 | TAAR1 (0.96) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| SCHEMBL15173398 | 0.82 | ADRA1A (0.51) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| SCHEMBL28041255 | 0.82 | ADRA1A (0.51) | ADRA1ATAAR1IDO1HTR2AAOC3 | |
| Hydrochloric Acid SCHEMBL1197172 | 0.82 | APLNR (0.61) | ADRA1ATAAR1IDO1HTR2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| CN-115322201-B | Macrocyclic column aromatic compound, and preparation method and application thereof | 湖南科技学院 | 2024-01-26 | — | — | CN | claimed |
| CN-115322201-A | Macrocyclic column aromatic compound and preparation method and application thereof | 湖南科技学院 | 2022-11-11 | — | — | CN | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| CN-105505128-B | Near-infrared light response self-repairing coating and preparation method thereof | 南京工业大学 | 2018-05-08 | — | — | CN | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| CN-105505128-A | Near-infrared light response self-repairing coating and preparation method thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2016-04-20 | — | — | CN | claimed |
| US-20250171582-A1 | CURING AGENT COMPOSITION FOR THERMOSETTING RESIN, EPOXY RESIN COMPOSITION, AND FIBER-REINFORCED COMPOSITE MATERIAL | TEIJIN LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| EP-4471073-A1 | CURING AGENT COMPOSITION FOR THERMOSETTING RESIN, EPOXY RESIN COMPOSITION, AND FIBER-REINFORCED COMPOSITE MATERIAL | Teijin Limited (JP) | 2024-12-04 | — | — | EP | disclosed |
| US-20240382488-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-12139686-B2 | Lubricating composition and method of lubricating an internal combustion engine | THE LUBRIZOL CORPORATION (US) | 2024-11-12 | — | — | US | disclosed |
| US-12091413-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-0858262-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5716965-A | Substituted 3-aminoquinuclidines | PFIZER INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997015190-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| EP-0585328-A1 | SUBSTITUTED 3-AMINOQUINUCLIDINES | PFIZER INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| CN-1068571-A | The 3-amino quinine ring that replaces | PFIZER (US) | 1993-02-03 | — | — | CN | disclosed |
| WO-1992020676-A1 | SUBSTITUTED 3-AMINOQUINUCLIDINES | PFIZER INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | ADRA1A 3834/4885TAAR1 3840/4885IDO1 3872/4885 |
| US-20240382488-A1 | NEK7 INHIBITORS | NEK7, NEK11, NEK2 | ADRA1A 834/4885TAAR1 2293/4885IDO1 3938/4885 |
| US-12091413-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | ADRA1A 862/4885TAAR1 2814/4885IDO1 3103/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | ADRA1A 183/4885TAAR1 173/4885IDO1 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.